Caribou Biosciences (CRBU) AI Stock Analysis

• Market Cap: $160.17M
• Dividend Yield: N/A
• Average Volume (3M): 812.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.64
• Revenue Growth: -72.45%
• EPS Growth: -28.60%
• Country: US
• Employees: 147
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.35
• Shares Outstanding: 93,123,240
• 10 Day Avg. Volume: 534,899
• 30 Day Avg. Volume: 812,548
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.26
• Enterprise Value/Revenue: -4.12
• Enterprise Value/Gross Profit: -5.19
• Enterprise Value/Ebitda: 0.25
• 1Y Price Target: $4.75
• Price Target Upside: 176.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 52 Neutral
• Price Target: $2.00 ▲(16.28% Upside)

Caribou Biosciences' overall score is driven primarily by its financial performance challenges, including declining revenues and operational losses. However, technical indicators show some positive price momentum, and the recent corporate event of regaining Nasdaq compliance supports investor confidence, contributing positively to the score. The absence of earnings call data limits the impact of future guidance and sentiment on the evaluation.

Positive Factors

Strong Equity Position

A strong equity base provides a financial buffer, enhancing stability and enabling the company to withstand operational challenges.

Low Leverage

Low leverage reduces financial risk and interest burden, allowing more flexibility for strategic investments and growth initiatives.

High Gross Profit Margin

A high gross profit margin indicates efficient cost management, which can support profitability as revenue scales.

Negative Factors

Declining Revenue

Significant revenue decline suggests challenges in market demand or competitive positioning, impacting long-term growth prospects.

Substantial Operational Losses

Large operational losses indicate inefficiencies and may require strategic changes to achieve sustainable profitability.

Negative Cash Flow

Negative cash flow strains liquidity and may necessitate external financing, impacting financial flexibility and growth capacity.

Caribou Biosciences Business Overview & Revenue Model

Company Description

Caribou Biosciences, Inc. is a biotechnology company focused on harnessing the power of CRISPR gene editing technology to develop innovative therapies for various diseases. The company operates primarily in the life sciences sector, offering products and services that enable researchers and developers to utilize CRISPR for gene editing applications. Caribou's core products include its proprietary CRISPR platform, which allows for precise genetic modifications, and it partners with academic institutions and pharmaceutical companies to advance cellular therapies and other biotechnological applications.

How the Company Makes Money

Caribou Biosciences generates revenue through multiple streams, including licensing agreements for its CRISPR technology, collaborations with pharmaceutical and biotechnology companies, and research grants. The company enters into partnerships that allow other firms to access its proprietary technologies for drug development, often receiving upfront payments, milestone payments based on development progress, and royalties on sales of resulting products. Additionally, Caribou may engage in grant-funded research projects that contribute to its income while furthering its technological advancements.

Caribou Biosciences Financial Statement Overview

Summary

Caribou Biosciences faces challenges with declining revenues, substantial operational losses, and negative cash flows, which overshadow its strong equity position and low leverage ratio. The company needs to address revenue growth and operational efficiency to improve financial health and sustainability.

Income Statement

Caribou Biosciences shows declining revenue, with the TTM (Trailing-Twelve-Months) revenue at $9.918 million compared to $34.477 million the previous year, indicating a significant drop. The gross profit margin for TTM is approximately 79.41%, suggesting high efficiency in cost management relative to revenue. However, the company is struggling with significant losses as evidenced by the negative net profit margin and EBIT margin, with a TTM net income of -$147.862 million. These figures reflect challenges in scaling revenue while controlling operational costs.

Balance Sheet

The company maintains a solid equity base with a stockholders' equity of $217.222 million in the TTM period. The debt-to-equity ratio stands at 0.12, indicating low leverage and a conservative capital structure. However, the ROE is negative due to the company's net losses, impacting profitability. The equity ratio is relatively strong, suggesting a healthy buffer of equity relative to total assets. Despite the strengths in capital structure, consistent losses pose a risk to long-term financial stability.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, with TTM free cash flow at -$142.196 million, indicating cash strain from operations. The ratio of operating cash flow to net income is less than 1, highlighting inefficient cash conversion. Though the company has substantial cash reserves, the negative cash flow trends point to potential liquidity issues if losses persist without external financing or revenue improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.92M	9.99M	34.48M	13.85M	9.60M	12.36M
Gross Profit	7.88M	6.07M	30.95M	10.21M	8.61M	-22.06M
EBITDA	-160.32M	-166.62M	-112.53M	-104.78M	-66.00M	-35.21M
Net Income	-147.86M	-149.10M	-102.07M	-99.42M	-66.92M	-34.31M
Balance Sheet
Total Assets	273.66M	313.31M	432.21M	373.76M	442.36M	36.05M
Cash, Cash Equivalents and Short-Term Investments	208.47M	209.54M	328.83M	247.66M	375.83M	15.95M
Total Debt	26.22M	26.49M	27.11M	27.75M	259.00K	1.58M
Total Liabilities	56.43M	60.36M	63.81M	72.89M	54.53M	59.48M
Stockholders Equity	217.22M	252.95M	368.40M	300.87M	387.82M	-23.44M
Cash Flow
Free Cash Flow	-142.20M	-143.08M	-104.90M	-98.02M	-35.64M	-34.53M
Operating Cash Flow	-137.72M	-138.20M	-93.29M	-90.97M	-32.52M	-33.22M
Investing Cash Flow	113.03M	86.61M	-68.18M	-93.25M	-176.40M	6.36M
Financing Cash Flow	4.71M	16.72M	154.30M	2.13M	433.43M	1.74M

Caribou Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.72
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Neutral. The current price of 1.72 is below the 20-day moving average (MA) of 1.86, below the 50-day MA of 1.92, and above the 200-day MA of 1.43, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.15 is Neutral, neither overbought nor oversold. The STOCH value of 18.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRBU.

Caribou Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRBU	52 Neutral	$160.17M	―	-68.93%	―	-72.45%	-28.60%
EDIT	51 Neutral	244.58M	-0.95	-176.57%	―	-41.97%	-20.86%
MGNX	46 Neutral	96.70M	-2.66	-78.08%	―	303.47%	73.70%
VXRT	44 Neutral	88.82M	-1.56	-172.28%	―	479.58%	46.15%
ZURA	43 Neutral	123.53M	-2.50	0.00%	―	0.00%	-50.20%
ELTX	30 Underperform	187.89M	-2.75	0.00%	―	0.00%	-4.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Caribou Biosciences Corporate Events

Caribou Biosciences Regains Nasdaq Compliance

On June 18, 2025, Caribou Biosciences announced that it had regained compliance with Nasdaq’s listing requirements, specifically maintaining a minimum closing bid price of $1.00 per share. This compliance, achieved between June 3 and June 17, 2025, ensures the company’s continued listing on the Nasdaq Global Select Market, which is crucial for its market presence and investor confidence.

Caribou Biosciences Confirms Director Elections and Auditor

On June 12, 2025, Caribou Biosciences, Inc. held its annual meeting of stockholders, where several key proposals were voted on. The election of two Class I directors, Scott Braunstein, M.D. and Ran Zheng, M.S., was confirmed, and the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, stockholders approved an amendment to the company’s certificate of incorporation to allow a reverse stock split and the potential adjournment of the annual meeting if necessary, although the latter was not needed as there was a quorum and sufficient votes for the proposals.